Jetrea ocriplasmin regulatory update

ThromboGenics said South Korea approved Jetrea ocriplasmin to treat vitreomacular adhesion (VMA), including when associated with macular hole diameter of <=400 microns. The company said South Korea is the fourth country in Asia to approve the drug, following Malaysia, Singapore and Taiwan.

Separately, ThromboGenics said the Spanish Ministry of Health approved the reimbursement of Jetrea for the indication. ThromboGenics said the reimbursement price of the test is EUR3,100 ($4,012.95) and that partner Alcon Inc. -- the ophthalmic unit of Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) -- will launch the test in Spain this month. Alcon has ex-U.S. commercialization rights to Jetrea. ...